phase 3 study

Eli Lilly Shelves Potential Alzheimer's Drug

Eli Lilly said Tuesday it is halting the development of an Alzheimer's treatment after studies showed the experimental drug semagacestat not only failed to slow the disease's progression, it actually reduced patients' cognition.